At the onset of COVID-19, life science organisations were severely impacted by stringent nationwide lockdowns and constantly faced challenges across business operations, managing production and distribution networks. Unavailability of employees at workplaces and travel restrictions largely disrupted supply chain and distribution systems. While a high surge in sales growth was visible during the second COVID-19 wave due to unprecedented demands of medicines, organisations also faced challenges in plant operations as multiple local regulatory approvals were required to ensure smooth movement of personnel and/or materials at site. Besides ramping up their production capacity and increasing work force, organisations had to adopt a flexible approach towards handling operations.
While compliance leaders remained fully committed in driving compliance through these times, a flexible approach needs to be adopted to ensure seamless business support without affecting the adequacy of their compliance programmes.
To know more about the common fraud trends and how life science organisations can protect themselves, download our document on Evolving fraud risks in ‘new normal’ for life science organisations.
